Table 2.
Survival and long‐term outcomes of patients with MEN1 gastrinoma
| Overall patients (n = 63) | |
|---|---|
| Follow‐up in years, median [range]* | 4.7 [0.25‐23.5] |
| Overall survival | |
| 5‐y, % (95% CI) | 83% (68‐92%) |
| 10‐y, % (95% CI) | 65% (47‐79%) |
| Liver metastases ** | 8 (14%) |
| Gastrinoma | 3 |
| NF‐pNET | 2 |
| Gastrinoma or NF‐pNET | 1 |
| Thymic NET | 1 |
| Unknown origin/unknown if MEN1 dpNET related | 1 |
| Death | 17 (27%) |
| MEN1‐related | 11 (65%) |
| Duodenopancreatic NET related | 8 |
| Thymic NET | 1 |
| Renal insufficiency caused by pHPT | 1 |
| Complication MEN1 pancreatic surgery | 1 |
| Non‐MEN1‐related | 5 (29%) |
| Unknown | 1 (6%) |
Abbreviations: dpNET, duodenopancreatic neuroendocrine tumor; MEN1, multiple endocrine neoplasia type 1; NF‐pNET, nonfunctioning pancreatic neuroendocrine tumor; NET, neuroendocrine tumor; pHPT, primary hyperparathyroidism.
*
Follow‐up until death or end of follow‐up.
**
Origin of liver metastases is based on the expert panel. Percentage is based on the group of patients without liver metastases at diagnosis (n = 58).